Aardvark Therapeutics Inc... (AARD)
Company Description
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.
Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation.
It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity.
The company was incorporated in 2017 and is based in San Diego, California.
| Country | United States |
| IPO Date | n/a |
| Industry | n/a |
| Sector | n/a |
| Employees | 17 |
| CEO | Dr. Tien-Li Lee M.D. |
Contact Details
Address: 4370 La Jolla Village Drive San Diego, California United States | |
| Website | https://aardvarktherapeutics.com |
Stock Details
| Ticker Symbol | n/a |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | n/a |
| CIK Code | n/a |
| CUSIP Number | n/a |
| ISIN Number | n/a |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Dr. Tien-Li Lee M.D. | Chief Executive Officer, Secretary & Director |
| Dr. Bryan Jones Ph.D. | Chief Operating Officer |
| Nelson B. Sun M.B.A. | Chief Financial Officer |
| Dr. Andreas Niethammer M.D., Ph.D. | Head of Translational Medicine |
| Dr. Dvorit Samid Ph.D. | Executive Vice President of Medical Affairs |
| Dr. Manasi Sinha Jaiman M.D., M.P.H. | Chief Medical Officer |
| Dr. Zhenhuan Zheng Ph.D. | Chief Research Officer |
| Tom Bicsak Ph.D. | Head of Regulatory Affairs & Quality |